Pheochromocytoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The pheochromocytoma market size was valued at USD 2.25 billion in 2025 and is estimated to grow from USD 2.36 billion in 2026 to reach USD 2.99 billion by 2031, at a CAGR of 4.84% during the forecast period (2026-2031). This report is Segmented by Offering (Diagnosis [Laboratory Tests and More], Treatment [Surgery and More]), Disease Type (Adrenal Pheochromocytoma, Extra-Adrenal Pheochromocytoma and Paraganglioma), Etiology (Sporadic, Hereditary), Disease Stage (Localized, Metastatic, and More), End User (Hospitals and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Value (USD).

Global Pheochromocytoma Market Trends and Insights

Rising Detection of Previously Unrecognized Tumors

Incidental identification is changing the pheochromocytoma market because many tumors are now found during imaging ordered for other conditions. The 2026 SEER analysis recorded a 5.8% annual increase in United States case counts from 1975 through 2022. A 2025 review argued that the often-cited incidence estimate of 1.9 cases per million person-years understates the number of cases identified as imaging access expands. A 2025 European congress report also found that annual PPGL incidence at 2 hospitals increased from 1.92 to 5.25 cases after 2020, and 51.9% of cases were identified incidentally. Imaging for other clinical indications, adrenal incidentaloma procedures, and post-COVID surveillance can therefore add patients without a dedicated PPGL screening campaign. This pattern supports demand for biochemical testing, functional imaging, surgical evaluation, and follow-up care across the pheochromocytoma market.

Expansion of Germline Genetic Testing and Cascade Screening

PPGL has a hereditary component in 30% to 40% of patients, which makes genetic evaluation more important than for many other solid tumors. The 2024 international consensus statement recommends germline testing for all pediatric PPGL patients and for first-degree relatives of confirmed mutation carriers. This shifts practice away from limited, gene-by-gene testing toward broader evaluation when clinically appropriate. Each confirmed hereditary case can lead to testing of 2 to 5 relatives, followed by multigene sequencing and continued biochemical or imaging surveillance. A September 2025 study demonstrated the feasibility and clinical utility of germline multigene panel testing in Japanese PPGL patients. The hereditary segment’s 7.22% CAGR reflects guideline-driven testing and surveillance activity within the pheochromocytoma market, rather than an increase in mutation prevalence.

Ultra-Rare Population Limits Commercial Trial Scale

The small patient population limits trial enrollment, commercial scale, and the speed of evidence generation. The United States records nearly 2,000 new PPGL diagnoses each year, while a 2025 systematic review reported pooled global incidence of 1.9 cases per million person-years. FIRSTMAPPP was the first randomized controlled PPGL trial and required multinational enrollment over multiple years to evaluate its primary endpoint. Eligibility rules based on SDHB status, VHL pathway activity, or SSTR2 expression divide an already small population into smaller groups. This makes single-arm studies and surrogate endpoints more common in advanced disease development. The resulting evidence base can delay payer acceptance and keeps the pheochromocytoma market dependent on specialist centers that can participate in international trials.

Other drivers and restraints analyzed in the detailed report include:

• Growth in Precision Therapies for Molecularly Defined Disease
• Radioligand Manufacturing and Theranostic Platform Investment
• Reimbursement Friction for Off-Label and Orphan Therapies

Segment Analysis

Treatment held 64.31% of the pheochromocytoma market share in 2025, supported by adrenalectomy and perioperative pharmacological stabilization for patients with localized disease. Laparoscopic or robotic adrenalectomy remains a core approach, with preoperative alpha-adrenergic blockade supporting hemodynamic control. Radiopharmaceutical treatment is gaining importance as 177Lu-DOTATATE evidence develops for advanced PPGL. Belzutifan also opened a new systemic treatment option after its 2025 approval for unresectable and metastatic disease. Cyclophosphamide, vincristine, and dacarbazine chemotherapy retains a narrower role in inoperable hereditary disease, particularly in SDHB-mutated metastatic cases. Calcium channel blockers and beta-blockers remain useful adjuncts to alpha-blockade, but generic competition limits their revenue contribution.

Diagnosis is the fastest-growing offering, with the pheochromocytoma market size for diagnosis forecast to rise at a 5.58% CAGR from 2026 to 2031. Functional imaging with 68Ga-DOTATATE PET/CT and multigene sequencing panels are central to this expansion in the pheochromocytoma market. A 2024 scoping review reported that 68Ga-DOTA-SST PET/CT can identify more than 90% of lesions in patients without known germline variants. Panels covering SDHA, SDHB, SDHC, SDHD, VHL, RET, NF1, and TMEM127 are replacing sequential single-gene testing as testing costs decline. Testing of relatives after a hereditary diagnosis creates repeat laboratory and surveillance activity that does not depend on new disease incidence. Genetic counseling, consent, and disclosure requirements also create recurring contact with specialist programs.

Adrenal pheochromocytoma held 83.44% of revenue in 2025 because adrenal tumors occur more often and follow a more established surgical pathway. Its biochemical workup commonly uses plasma fractionated metanephrines, which supports reproducible testing at tertiary centers. A Portuguese referral-center study published in 2024 recorded an incidence trend of 5.3 cases per million from 2012 through 2024. The study found metastatic disease only among hereditary cases, reinforcing the value of genetic assessment at diagnosis. Adrenal disease is expected to remain the majority disease type through 2031. Its share may narrow gradually as imaging identifies more lesions outside the adrenal gland.

Extra-adrenal pheochromocytoma and paraganglioma is forecast to grow at a 7.52% CAGR from 2026 to 2031 within the pheochromocytoma market. The 2024 scoping review reported 91% to 93% detection rates for 68Ga-DOTA-SST PET/CT in extra-adrenal and paraganglioma lesions without known germline variants. Limited 68Ga availability in Latin America shifts care toward 18F-FDOPA, which the same review associated with 74% detection efficiency. This difference shows how imaging capacity can influence local access to diagnosis. Head and neck paragangliomas are often non-secreting and may be identified later than other PPGL forms. Wider access to functional imaging is therefore important for the disease type’s faster growth.

Complete Report Scope:

• By Offering
  • Diagnosis
    • Laboratory Tests
    • Imaging Tests
    • Genetic Testing
  • Treatment
    • Preoperative Medical Stabilization
    • Surgery
    • Radiopharmaceutical Therapy
    • Systemic Targeted Therapy
    • Chemotherapy
    • Local and Supportive Therapy
• By Disease Type
  • Adrenal Pheochromocytoma
  • Extra-Adrenal Pheochromocytoma and Paraganglioma
• By Etiology
  • Sporadic
  • Hereditary
• By Disease Stage
  • Localized
  • Regional or Locally Advanced
  • Metastatic
  • Recurrent
• By End User
  • Hospitals
  • Specialty Endocrinology Centers
  • Oncology Centers
  • Diagnostic Laboratories
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.61% of the pheochromocytoma market share in 2025. The region benefits from high-volume academic referral centers, established reimbursement for 68Ga-DOTATATE PET/CT, and early commercial use of belzutifan after FDA approval in May 2025. United States care is increasingly concentrated in institutions that can provide functional imaging, SSTR2 assessment, radionuclide therapy, and radiation safety support. This can improve coordination for complex patients, but it can also concentrate capacity in a limited number of centers. Canada has a different access pattern because provincial formulary negotiations can trail United States approvals by 12 to 24 months. Perspective Therapeutics’ Somerset facility illustrates the concentration of alpha-particle radioligand supply infrastructure in the northeastern United States.

Europe represents a substantial part of the global pheochromocytoma market through national reference networks in Germany, France, and the United Kingdom. France’s COMETE network and other referral systems centralize multidisciplinary care and support longitudinal patient records. The EU joint clinical assessment framework can complicate access for therapies supported by single-arm orphan studies before national price negotiations take place. This process can add 12 to 18 months to effective access in the EU5. Spain, Italy, and Central and Eastern European countries may rely on compassionate access or named-patient programs for PPGL use of PRRT beyond the approved gastroenteropancreatic neuroendocrine tumor indication. These differences maintain an access gap among European health systems.

Asia-Pacific is the fastest-growing geography, with the pheochromocytoma market size projected to grow at a 6.85% CAGR from 2026 to 2031. Japan’s 2025 revised clinical guideline incorporated updated tumor classification, pediatric genetic testing recommendations, radionuclide therapy descriptions, and head and neck paraganglioma management. China’s oncology infrastructure and rising hereditary tumor awareness in India also support regional expansion in the pheochromocytoma market. Japan’s 131I-MIBG insurance coverage has provided a reimbursement precedent for later radionuclide therapy adoption. The Middle East, Africa, and South America remain limited by gaps in specialist and nuclear medicine capacity. Brazil has potential for further growth because of targeted oncology investment programs and greater genomic medicine funding.

List of Companies Covered in this Report:

• AstraZeneca
• Bausch Health
• Bayer
• Curium Pharma
• Exelixis, Inc.
• GE HealthCare Technologies Inc.
• Hikma Pharmaceuticals
• ITM Isotope Technologies Munich SE
• Jazz Pharmaceuticals plc
• Lantheus Holdings, Inc.
• Merck
• Novartis
• Nxera Pharma Co., Ltd.
• Ono Pharmaceutical
• Perspective Therapeutics, Inc.
• Pfizer
• Siemens Healthineers
• Teva Pharmaceutical Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support